NovoCare Pharmacy Review: The Only Seller Whose Peptide Has an NDC — and a Banner It Cannot Support
NovoCare Pharmacy is the easiest provider on this site to grade on provenance and the hardest to grade on language. What it dispenses is unambiguous: Wegovy and Ozempic, made by the company that ran the trials, with the National Drug Code of every covered presentation printed in the programme terms — a level of product identification no compounded-peptide seller comes close to. What fills the prescription is a chain of three companies you have to read the terms to find. And the sentence across the top of every page, "We are FDA-approved," describes something the Food, Drug, and Cosmetic Act does not offer to pharmacies at all — the same wording FDA cited a competitor for in June 2026.
Dispenses
FDA-approved only
Evidence
Phase 3 trials
Pharmacy
Named
FDA letter
None found
By Grant Delaney, Research Editor·
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.novocarepharmacy.com. A link is not a recommendation to take anything.
Provenance
What NovoCare Pharmacy actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
FDA-approved3 products
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
Wegovy® pen (semaglutide injection, 0.25–2.4 mg) — $199 a month for the first two fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349 a month for 0.25 mg through 2.4 mg. Wegovy® HD 7.2 mg is priced separately at $399 a month. Self-pay only — the programme does not accept insurance.
Wegovy® tablets (oral semaglutide, 25 mg) — $149 a month for the 1.5 mg and 4 mg strengths; the 4 mg rate is stated to run only until August 31, 2026, after which it becomes $199. A month is defined as one bottle of 30 tablets.
Ozempic® pen (semaglutide injection, 0.25–2 mg) — $199 a month for the first two fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349 a month for 0.25 mg to 1 mg and $499 a month for 2 mg.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
Semaglutide · Rx
Phase 3 trials
Semaglutide · Rx
Phase 3 trials
Semaglutide · Rx
Phase 3 trials
3
Products with a human trial
Out of 3 reviewed here.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from NovoCare Pharmacy’s own page, with the page it came from. Grading a paraphrase would prove nothing.
Wegovy® pen (semaglutide injection, 0.25–2.4 mg)
Claim matches the trials
“Starting at $199 per month … Patients new to the Wegovy® Savings Offer and NovoCare® Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg. Offer is for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.”
NCT03548935STEP 1 — Phase 3, completed, n=1,961. Once-weekly semaglutide 2.4 mg versus placebo in adults with overweight or obesity, 68 weeks.
The claim here is entirely about price and eligibility, and the price statement is complete: both the introductory figure and the figure it reverts to are printed, with the date the switch happens. On efficacy the page defers to the approved label rather than characterising the drug itself, which is the correct thing for a dispensing pharmacy to do.1,2
Wegovy® tablets (oral semaglutide, 25 mg)
Claim matches the trials
“Wegovy® pill Starting at $149 per month … Patients pay $149 for each month of 1.5 mg and 4 mg. 4 mg offer only available until August 31, 2026, then $199 per month for 4 mg. One month defined as 1 bottle of 30 tablets.”
NCT05564117OASIS 4 — Phase 3, completed, n=307. Oral semaglutide 25 mg once daily versus placebo in adults with overweight or obesity, 64 weeks. Results are posted on the registry.
The oral presentation has its own completed phase 3 programme rather than borrowing the injectable's — a distinction worth insisting on, because an oral and an injectable version of the same molecule are not interchangeable evidence. The pricing footnote is specific to the point of being awkward, which on this subject is the right failure mode.3
Ozempic® pen (semaglutide injection, 0.25–2 mg)
Claim matches the trials
“Ozempic® pen Starting at $199 per month … then $349 per month for Ozempic® 0.25 mg, 0.5 mg or 1 mg and $499 per month for Ozempic® 2 mg.”
NCT03548935STEP 1 — Phase 3, completed, n=1,961. Cited here for the molecule. Ozempic's own approval rests on the SUSTAIN type 2 diabetes programme, not on STEP; the two indications are not interchangeable.
Priced and labelled as what it is. The programme terms restrict participation to patients prescribed the drug for an FDA-approved indication, which for Ozempic is type 2 diabetes — so a reader arriving for weight loss is being sold the wrong product, and the terms say so where the pricing table does not.1
Dispensing chain
Who actually fills your prescription
Pharmacy named
CoAssist Pharmacy, LLC d/b/a NovoCare® Pharmacy
CenterWell® Pharmacy
AssistRx (patient intake and benefits, not a dispenser)
NovoCare® Pharmacy is a programme name, not a pharmacy. Novo Nordisk's own terms disclose three third parties by name: AssistRx runs intake and benefits investigation; CoAssist Pharmacy, LLC — described as "[a] licensed pharmacy in all 50 US states and territories that, for purposes of this program, is CoAssist Pharmacy d/b/a NovoCare® Pharmacy" — receives the prescription; and "[t]hese cash/self-pay prescriptions are filled by Centerwell® Pharmacy or CoAssist Pharmacy d/b/a NovoCare® Pharmacy." A footnote on the home page says the same thing more briefly: "CoAssist Pharmacy is a dispensing pharmacy for NovoCare® Pharmacy." Naming all three is more than any compounded-peptide seller reviewed here manages. The gap is that a patient cannot then look CoAssist up from the site: no licence number, no address and no link is published, and coassistpharmacy.com resolves in DNS but returned no response on August 7, 2026. The identifiers in this review — Florida community pharmacy licence PH34564 and NPI 1710671854, at 2400 Sand Lake Rd Ste 200b, Orlando, FL — came from state and federal registries, not from Novo.
There is no lot-testing page, and there should not be one. A finished drug made under an approved application is covered by the manufacturer's CGMP obligations and its released specification, and a per-lot certificate is not something a retail pharmacy publishes for a branded product. What stands in its place here is stronger than any of it: the programme terms print the National Drug Code of every covered presentation — 0169-4525-14 through 0169-4524-14 for the Wegovy pens, 00169-4415-31 and 00169-4404-31 for the tablets, 0169-4181-13 through 0169-4772-12 for the Ozempic pens. An NDC identifies the labeller, the product and the package size, and it is checkable in FDA's own listing database by anyone. No compounded-peptide seller on this site publishes anything with that property, because compounded preparations do not have NDCs to publish.
All 50 US states and territories, per Novo Nordisk's own programme terms
Novo's terms describe CoAssist as "[a] licensed pharmacy in all 50 US states and territories." CoAssist Pharmacy, LLC holds Florida community pharmacy licence PH34564, listed as Clear/Active, originally issued May 5, 2023 and expiring February 28, 2027, and carries NPI 1710671854 as a community/retail pharmacy at 2400 Sand Lake Rd Ste 200b, Orlando, FL 32809. A programme this size will hold non-resident licences in the other 49; those were not individually checked for this review and are not asserted here.
A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves — matched on full company name rather than substring, because a substring match attaches one company’s regulatory history to another — returns no entry for NovoCare Pharmacy (CoAssist Pharmacy, LLC d/b/a NovoCare® Pharmacy (a Novo Nordisk programme)). That is a statement about those three waves as of August 2026, not a claim that no action exists anywhere.
Assessment
What holds up, and what does not
What holds up
Every product is an approved finished drug with a published National Drug Code, made by the company that ran the registration trials. There is no question about what is in the vial, who made it, or what evidence sits behind it.
The dispensing chain is disclosed by name — AssistRx, CoAssist Pharmacy and CenterWell Pharmacy are all identified in the programme terms, which is more than most telehealth brands publish about the pharmacy filling their prescriptions.
Ongoing prices are printed alongside the introductory ones, with the date the introductory rate ends. $199 becoming $349 on January 1, 2027 is on the page, not buried in a cancellation flow.
The oral 25 mg presentation rests on its own completed phase 3 trial rather than borrowing the injectable's evidence — the tablets and the pens are separately supported, and the registry record for each is public.
No FDA warning letter. A search of the 113 telehealth warning letters issued in the September 2025, February 2026 and June 2026 waves, matched on full company name, returns nothing for Novo Nordisk, NovoCare, CoAssist or CenterWell.
Self-pay is stated as self-pay. The terms say plainly that insurance is not accepted and that money spent does not count toward a deductible or out-of-pocket limit — the kind of disclosure that usually has to be reverse-engineered.
What does not
"We are FDA-approved" sits above the fold on every page, and it describes something that does not exist. FDA grants no approval or licence to a pharmacy; the drugs are approved, the seller cannot be. FDA said so in writing to a competitor in June 2026, in almost the same words.
You cannot look up your own dispensing pharmacy. CoAssist is named but not linked, no licence number or address is published, and coassistpharmacy.com served no page when checked on August 7, 2026 — so the identifiers in this review had to come from Florida's licence database and NPPES rather than from Novo.
Every headline figure is an introductory rate. $199 is two fills; $149 on the 4 mg tablet expires August 31, 2026. The ongoing figures are printed, but they are printed in footnotes lettered a through f beneath the buttons.
The Ozempic listing sits in a weight-loss shop window while the programme terms restrict participation to patients prescribed the drug for an FDA-approved indication — and Ozempic's approved indication is type 2 diabetes. Those two facts are on different pages.
The price gap between presentations of the same molecule is never explained. Ozempic 2 mg is $499 a month against $349 for 1 mg of the identical drug, and $149 for 4 mg of it as a tablet.
There is no prescriber here. The programme dispenses against a prescription you have to obtain elsewhere, and the "connect with a prescriber" route hands you to third-party telehealth whose own practices are outside anything Novo publishes.
Verdict
The bottom line
If the question is "what am I actually being dispensed," this is the best answer available in the category, and it is not close. An approved finished drug, a published NDC for every presentation, phase 3 trials with registry records and posted results, and the dispensing pharmacies named in the terms. The failures are failures of language rather than of provenance: a banner claiming a regulatory status that does not exist for pharmacies, introductory pricing dressed as pricing, and a named dispensing pharmacy you cannot actually look up. Those are worth knowing about. They are a different order of problem from not being told what is in the vial.
Opens www.novocarepharmacy.com. A link is not a recommendation to take anything.
The claim on the banner is the one thing here that is not checkable
Load any page on novocarepharmacy.com and the first sentence you meet, in a bar above the navigation, is: "We are FDA-approved. Compound semaglutides are not. Find out about the risks here." The second sentence is correct and important. Compounded semaglutide is not FDA-approved, and this site says so on every page it can.
The first sentence is a category error, and an unusually consequential one because of who is making it. FDA approves drugs, biologics and devices. It does not approve, licence, certify or register pharmacies in any way that produces a status a pharmacy could describe itself as holding — state boards of pharmacy license pharmacies. This is not an inference. FDA put it in writing on June 8, 2026, in a warning letter to a competitor that had described its supplying pharmacies as "FDA-licensed": "Compounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities. The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities. Therefore, representing a compounding pharmacy or outsourcing facility as 'FDA-approved' or 'FDA-licensed' is false and misleading, as these terms imply a formal authorization that FDA does not grant." 4
Read the two side by side. A telehealth firm said its pharmacy was FDA-licensed and received a warning letter. Novo Nordisk's pharmacy says "we are FDA-approved" in a font size you can read from across a room. The difference in the underlying facts is real — Novo's drugs genuinely are approved and the competitor's compounded preparations genuinely are not — but the sentence does not say "our drugs are approved." It says we are. On a page whose entire purpose is to teach consumers to distinguish approved product from compounded product, that is the one sentence that ought to have survived legal review.
It is worth being precise about what this finding is and is not. NovoCare holds no warning letter. Nothing here suggests one is coming, and a claim of this kind from the holder of the approvals in question is a long way from a compounder borrowing regulatory credit it does not have. It is recorded because this site grades sellers on whether their words match the regulatory reality, and this one does not.
NovoCare Pharmacy is not a pharmacy
The name is a programme, not an entity. Working out who actually fills the prescription takes a trip to the terms, and the terms are unusually forthcoming once you get there.
Three companies are disclosed by name. AssistRx runs patient intake and the benefits investigation. CoAssist Pharmacy, LLC — "[a] licensed pharmacy in all 50 US states and territories that, for purposes of this program, is CoAssist Pharmacy d/b/a NovoCare® Pharmacy" — receives the prescription. And then: "These cash/self-pay prescriptions are filled by Centerwell® Pharmacy or CoAssist Pharmacy d/b/a NovoCare® Pharmacy." The home page carries the short version in footnote f: "CoAssist Pharmacy is a dispensing pharmacy for NovoCare® Pharmacy."
Name three third parties, including the one that touches your medicine, and you are ahead of almost everyone in this market. Two of the three other providers reviewed on this site will not name the compounding pharmacy that makes their peptides at all.
Where it stops short is the next step. CoAssist is a name and nothing else: no licence number, no address, no link. On August 7, 2026, coassistpharmacy.com resolved in DNS but returned no response at all — a connection reset, not a holding page. So a patient handed the name of the company that will dispense their drug cannot look it up from the site that named it. The identifiers in this review — Florida community pharmacy licence PH34564, listed Clear and running to February 28, 2027; NPI 1710671854, a community/retail pharmacy at 2400 Sand Lake Rd Ste 200b, Orlando, Florida — came from the Florida Department of Health's licence verification service and from NPPES. They are public, they check out, and none of them came from Novo Nordisk.
What the trials actually found, and which trial belongs to which product
The pharmacy defers to the label on efficacy, which is the correct behaviour for a dispenser and leaves this review to do the evidence reporting itself. Three approved presentations, three distinct evidence bases, and they are not interchangeable.
The injectable semaglutide 2.4 mg sold as Wegovy rests on STEP 1: 1,961 adults with overweight or obesity, randomised to once-weekly semaglutide 2.4 mg or placebo for 68 weeks, published in the New England Journal of Medicine in March 2021. 12 That is the trial that reset expectations for what a peptide could do to body weight, and its registry record — phase 3, completed, enrolment 1,961 — is public and posted. 2
The tablets are a separate programme. Oral semaglutide 25 mg was tested in OASIS 4: 307 adults, 64 weeks, phase 3, completed, results posted on ClinicalTrials.gov, published in the New England Journal of Medicine in September 2025. 3 Three hundred and seven participants is a sixth of STEP 1, and a reader should hold the two findings with correspondingly different confidence — but a separately tested oral presentation is still a categorically stronger position than an oral formulation of a peptide that has only ever been injected in a trial, which is what the compounded market routinely sells.
The 7.2 mg high-dose pen priced at $399 has its own trial too, STEP UP: 1,407 adults, phase 3b, completed, published in Lancet Diabetes & Endocrinology in November 2025. 5
And Ozempic, which the pricing table lists next to Wegovy as though the choice between them were about presentation, is approved for type 2 diabetes. Novo's terms are explicit that participation requires a prescription "for an FDA-approved indication." A reader arriving from a weight-loss search and choosing the cheaper-looking Ozempic pen is choosing a drug approved for something else. Both of those statements are on the site. They are not on the same page.
The pricing is honest and still needs decoding
Six footnotes, lettered a through f, sit under four buttons. They contain, between them, everything you need — which is more than most of this market offers — arranged so that the number you remember is the smallest one.
The pattern is the same throughout: a headline introductory rate, a stated number of fills, a date, and the figure it becomes. $199 a month buys the first two fills of Wegovy 0.25 mg or 0.5 mg through December 31, 2026, after which every strength from 0.25 mg to 2.4 mg is $349. The 4 mg tablet is $149 until August 31, 2026 and $199 after. Ozempic follows the injectable pattern, except that the 2 mg strength lands at $499 — $150 a month more than 1 mg of the same molecule, unexplained.
Two things are worth saying in the pharmacy's favour. The ongoing price is actually printed, with its date, which is the single most-omitted fact in this entire category. And the self-pay disclosure is unusually blunt: the tooltip states that by paying outside insurance, "any money spent will not count toward your out-of-pocket limits or deductible." That is a real cost, it is easy to leave out, and it has not been left out.
Where this sits against the rest of the market
The reason to review the manufacturer's own pharmacy on a site about peptides is that it establishes the ceiling. Everything about provenance that a compounded-peptide seller cannot give you, this can. The NDC of every presentation is printed in the terms, so the labeller, the product and the package size are all identifiable in FDA's own listing database by anyone who wants to check. The trials are registered, completed, published and posted. The dispensing pharmacies are named.
That ceiling is worth carrying to the other reviews on this site. When a seller of compounded sermorelin says its medication is "lab tested for quality and potency" but will not say which pharmacy compounded it, the gap between that and a printed NDC is the whole distance between a claim and a fact. Read what the evidence for semaglutide actually shows, and what it does not, before deciding that distance does not matter.
What this review cannot tell you is whether any of it is right for you, and it will not try. There is no prescriber here — the programme dispenses against a prescription you obtain elsewhere, and the "connect with a prescriber" path hands you to third-party telehealth operating under practices Novo does not publish. That is a real gap in a chain that is otherwise the most legible in the category.
Questions
Frequently asked questions
Is NovoCare Pharmacy really FDA-approved?▾
No, and nothing can be. FDA approves drugs; it does not approve, licence or certify pharmacies, which are licensed by state boards of pharmacy. The drugs NovoCare dispenses — Wegovy and Ozempic — genuinely are FDA-approved, and that is a meaningful distinction from compounded semaglutide. But the banner sentence "We are FDA-approved" claims a status the Food, Drug, and Cosmetic Act does not create. FDA stated this in writing on June 8, 2026, in a warning letter to a telehealth competitor that had described its supplying pharmacies as "FDA-licensed."
Who actually fills my prescription?▾
One of two pharmacies, both named in Novo Nordisk's programme terms. CoAssist Pharmacy, LLC trades as NovoCare® Pharmacy and receives the prescription; CenterWell® Pharmacy may fill and ship it instead. A third company, AssistRx, handles intake and benefits but does not dispense. Naming all three is better disclosure than most of this market offers. What is missing is any way to check: no licence number, no address and no working website is published for CoAssist, so the Florida licence PH34564 and NPI 1710671854 in this review came from state and federal registries rather than from the site.
What does it actually cost after the introductory period?▾
The Wegovy pen is $199 a month for the first two fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349 a month for every strength from 0.25 mg to 2.4 mg. The 7.2 mg high-dose pen is $399. Wegovy tablets are $149 a month at 1.5 mg and 4 mg, with the 4 mg rate stated to end on August 31, 2026 and become $199. Ozempic follows the same pattern at $199 then $349, except that 2 mg is $499. Every one of those figures is printed on the site, in footnotes lettered a through f. All were read on August 7, 2026.
Does NovoCare have an FDA warning letter?▾
No. A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves, matched on full company name rather than substring, returns no entry for Novo Nordisk, NovoCare, CoAssist Pharmacy or CenterWell Pharmacy. That is a statement about those three waves as of August 2026, not a claim that no regulatory action exists anywhere in the world.
Why is Ozempic listed next to Wegovy if they do different things?▾
Both contain semaglutide, and NovoCare dispenses both, so both appear in the same pricing table. Their approvals are not the same: Wegovy is approved for chronic weight management, Ozempic for type 2 diabetes. Novo's programme terms restrict participation to patients prescribed the drug for an FDA-approved indication — so choosing the cheaper-looking Ozempic pen for weight loss is choosing a drug approved for a different condition. Both facts are published. They are not published on the same page, and the pricing table is the page most people will read.
How does this compare with buying compounded semaglutide?▾
On provenance it is not a close comparison, and this site will not pretend otherwise. An approved finished drug carries a National Drug Code identifying the labeller, product and package size, checkable in FDA's own database — NovoCare prints every one of them in its terms. A compounded preparation has no NDC, because it is not an approved product; FDA does not review compounded drugs for safety, effectiveness or quality, and the pharmacy that made yours is frequently not named. On price the comparison runs the other way, sharply. Which of those matters more is a decision this site does not make for you, and neither the price nor the provenance tells you whether the drug is appropriate for you at all — that is a conversation with a clinician.
Is the oral tablet the same evidence as the injection?▾
No, and it is worth insisting on the distinction because the compounded market routinely blurs it. Injectable semaglutide 2.4 mg rests on STEP 1: 1,961 participants, 68 weeks, phase 3, published in the New England Journal of Medicine in 2021. The 25 mg tablet rests on OASIS 4: 307 participants, 64 weeks, phase 3, completed with results posted, published in the same journal in September 2025. Both are real phase 3 evidence for the presentation actually being sold, which is the standard. But 307 is a sixth of 1,961, and the confidence a reader attaches to each should differ accordingly.
Glossary
Key terms
NDC (National Drug Code)
A three-segment code identifying the labeller, the specific product, and the package size of a drug listed with FDA. Compounded preparations do not have one, which is why a printed NDC is the strongest single provenance signal a seller can offer.
Self-pay / cash programme
Buying outside insurance at a price the manufacturer sets. Money spent this way does not count toward a deductible or out-of-pocket maximum — NovoCare states this in a tooltip rather than leaving it to be discovered.
Approved indication
The specific condition an FDA approval covers. Semaglutide is approved as Wegovy for chronic weight management and as Ozempic for type 2 diabetes; the molecule being the same does not make the approvals interchangeable.
Warning letter
A public regulatory communication telling a firm that FDA has identified violations. It is not a finding of illegal activity and not a shutdown. On this site a letter is disclosed, dated and quoted from its body — never treated as disqualifying.
Method
How we checked this
Claims read first-party
Every quoted claim was read off NovoCare Pharmacy's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Sources
References
1.Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
2.Novo Nordisk A/S (2026). Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity (STEP 1), NCT03548935 — phase 3, completed, enrolment 1,961. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT03548935
3.Wharton S, Lingvay I, Bogdanski P, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine 393(11):1077-1087. https://pubmed.ncbi.nlm.nih.gov/40934115/
5.Wharton S, Freitas P, Hjelmesaeth J, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes & Endocrinology 13(11):949-963. https://pubmed.ncbi.nlm.nih.gov/40961952/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.